{
    "paper_id": "be940c239b0592a1ea984afc16b7c6f0bfd98e32",
    "metadata": {
        "title": "Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa",
        "authors": []
    },
    "abstract": [],
    "body_text": [
        {
            "text": "ated with the omicron variant during the period from November 15 to December 7 in South Africa, which we dubbed a proxy for dominance of the omicron variant (omicron proxy period), against estimates of vaccine effectiveness between September 1 and October 30, when the delta variant was dominant (comparator period).",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "In our study, we used a test-negative design and data-exclusion rules to obtain estimates of vaccine effectiveness 4 (Table S1 ), according to the following formula: 1 \u2212 odds ratio for Covid-19 hospitalization in the vaccinated population, where the odds ratio was calculated with the use of logistic regression after adjustment for confounders of age, sex, previous Covid-19 infection, surveillance week, geographic location, and the number of CDC risk factors. In this analysis, Covid-19 hospitalization was a dependent variable, and vaccination status was included as an independent variable.",
            "cite_spans": [
                {
                    "start": 115,
                    "end": 116,
                    "text": "4",
                    "ref_id": "BIBREF5"
                }
            ],
            "ref_spans": [
                {
                    "start": 117,
                    "end": 126,
                    "text": "(Table S1",
                    "ref_id": "TABREF0"
                }
            ],
            "section": ""
        },
        {
            "text": "We then performed three sensitivity analyses on different subsets of data during the omicron proxy period. First, we performed PCR tests showing S-gene target failure as an indication of omicron infection. Second, we included only PCR results obtained from patients in Gauteng province, given the geographic concentration of the omicron variant during the study period. Third, we limited PCR test results to those obtained from patients who had been hospitalized (e.g., respiratory medical admissions), with the latter used as a proxy for identifying tests among a symptomatic population (Table S4) .",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 588,
                    "end": 598,
                    "text": "(Table S4)",
                    "ref_id": null
                }
            ],
            "section": ""
        },
        {
            "text": "We analyzed 133,437 PCR test results that had been obtained during the comparator period, of which 38,155 (28.6%) had been obtained at least 14 days after the patient had received the second dose of vaccine. For the proxy omicron period, we analyzed 78,173 PCR test results, of which 32,325 (41.4%) had been obtained at least 14 days after the second dose ( Table 1 ). The overall test positivity was 6.4% during the comparator period and 24.4% during the proxy omicron period, whereas the Covid-19 admission rate was 10.8% and 2.2%, respectively, as a percentage of positive PCR test results. Patients with positive cases were younger during the proxy omicron period than during the comparator period (Table S3) .",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 358,
                    "end": 365,
                    "text": "Table 1",
                    "ref_id": "TABREF0"
                },
                {
                    "start": 702,
                    "end": 712,
                    "text": "(Table S3)",
                    "ref_id": null
                }
            ],
            "section": ""
        },
        {
            "text": "During the proxy omicron period, we found a vaccine effectiveness of 70% (95% confidence interval [CI], 62 to 76), a finding that was supported by the results of all sensitivity tests. This measure of vaccine effectiveness was significantly different from that during the comparator period, when the rate was 93% (95% CI, 90 to 94) against hospitalization for Covid-19 (Table 2) .",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 369,
                    "end": 378,
                    "text": "(Table 2)",
                    "ref_id": "TABREF1"
                }
            ],
            "section": ""
        },
        {
            "text": "Thus, during the proxy omicron period, we saw a maintenance of effectiveness of the BNT162b2 vaccine (albeit at a reduced level) against hospital admission for Covid-19 that was presumed to have been caused by the omicron variant as compared with the rate associated with the delta variant earlier in the year. The addition of a booster dose of vaccine may mitigate this reduction in vaccine effectiveness. 5 Shirley Collie, B.Sc. Jared Champion, M.Sc. * The overall estimates of vaccine effectiveness were calculated according to a test-negative design after adjustment for confounders. The three sensitivity analyses included the results of polymerase-chain-reaction (PCR) tests showing S-gene target failure (as an indication of omicron infection), PCR results obtained only from patients in Gauteng province, and PCR results obtained only from patients who had been hospitalized (i.e., symptomatic population).",
            "cite_spans": [
                {
                    "start": 407,
                    "end": 408,
                    "text": "5",
                    "ref_id": "BIBREF6"
                }
            ],
            "ref_spans": [],
            "section": ""
        }
    ],
    "bib_entries": {
        "BIBREF1": {
            "ref_id": "b1",
            "title": "South Africa glenda . gray@ mrc . ac",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "SARS-CoV-2 sequencing update",
            "authors": [],
            "year": 2021,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa",
            "authors": [
                {
                    "first": "Jrc",
                    "middle": [],
                    "last": "Pulliam",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Van Schalkwyk",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Govender",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "https:/www.medrxiv.org/content/10.1101/2021.11.11.21266068v2"
                ]
            }
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Science brief: evidence used to update the list of underlying medical conditions associated with higher risk for severe COVID-19",
            "authors": [],
            "year": 2021,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant",
            "authors": [
                {
                    "first": "Lopez",
                    "middle": [],
                    "last": "Bernal",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Andrews",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Gower",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "N Engl J Med",
            "volume": "385",
            "issn": "",
            "pages": "585--94",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Barda",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Dagan",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Cohen",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "Lancet",
            "volume": "398",
            "issn": "",
            "pages": "2093--100",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": ", M.B., B.Ch. National Institute of Communicable Diseases Johannesburg, South Africa",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "Hospitalization for Covid-19 and Test Positivity before and during the Proxy Omicron Period in Gauteng Province (September-December 2021). the rate of misclassification of unvaccinated controls was estimated to be no more than 10%.",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "Effectiveness of Two Doses of BNT162b2 Vaccine before and during Proxy Omicron Period.*",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}